Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1812 results
October 2021
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edemaRegulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
-
Media ReleaseSandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibioticsSandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading…
-
Expanding a new digital healthcare solution across chronic heart disease management
More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.
-
Media ReleaseNovartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosisNovartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III…
-
Media ReleaseSandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic DrugsCompany previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…
-
StatementEnabling our associates to work safely on our sites
September 2021
-
Media ReleaseNovartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticariaResults from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…
-
Media ReleaseNovartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissionsReached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and…
-
Media ReleaseNovartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malariaNovartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
-
Media ReleaseNew data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasisNew findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
-
Media ReleaseNovartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patientsData analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Pulse UpdateFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Pagination
- ‹ Previous page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- …
- 151
- › Next page